Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tozinameran + riltozinameran (BioNTech SE)
- Development stage
- Discontinued
- Lead developer
- Pfizer
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
**Tozinameran + riltozinameran** is the bivalent original/Omicron BA.1 formulation of the Pfizer-BioNTech COVID-19 mRNA vaccine marketed as **Comirnaty Original/Omicron BA.1**. It contains equal 15-microgram amounts of two lipid-nanoparticle-formulated nucleoside-modified mRNAs: tozinameran, encoding the ancestral SARS-CoV-2 spike protein, and riltozinameran, encoding the Omicron BA.1 spike protein. Following intramuscular administration, translated spike antigens stimulate neutralising antibody and cellular immune responses against SARS-CoV-2. It was authorized as a booster vaccine for prevention of COVID-19; later variant-updated Comirnaty formulations superseded the BA.1 product. ([ema.europa.eu](https://www.ema.europa.eu/en/documents/variation-report/comirnaty-h-c-005735-ii-0140-epar-assessment-report-variation_en.pdf))
- Brand names
- Comirnaty Original/Omicron BA.1
- Other names
- tozinameran + riltozinamerantozinameran/riltozinameran
02
Targets
80S ribosome (Ribosome and ribosomal components)SARS-CoV-2 spike
Beyond the preview
Go deeper on tozinameran + riltozinameran (BioNTech SE).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tozinameran + riltozinameran (BioNTech SE).